1991
A Phase II Trial of Cyclosporin A in the Treatment of Refractory Metastatic Colorectal Cancer
Murren J, Ganpule S, Sarris A, Durivage H, Davis C, Makuch R, Handschumacher R, Marsh J. A Phase II Trial of Cyclosporin A in the Treatment of Refractory Metastatic Colorectal Cancer. American Journal Of Clinical Oncology 1991, 14: 208-217. PMID: 2031507, DOI: 10.1097/00000421-199106000-00007.Peer-Reviewed Original ResearchConceptsPhase II trialCyclosporin AII trialColorectal cancerEuropean Cooperative Oncology Group performance statusRefractory metastatic colorectal cancerSignificant toxicityRefractory colorectal cancerMetastatic colorectal cancerFlu-like symptomsMeasurable diseaseStable diseaseStarting doseColorectal malignancyObjective responsePerformance statusImmunosuppressive agentsInitial doseDose reductionColon cancerPatientsHuman neoplasmsExperimental modelCancerDoseHigh‐dose cisplatin plus dacarbazine in the treatment of metastatic melanoma
Murren J, Derosa W, Durivage H, Davis C, Makuch R, Portlock C. High‐dose cisplatin plus dacarbazine in the treatment of metastatic melanoma. Cancer 1991, 67: 1514-1517. PMID: 2001539, DOI: 10.1002/1097-0142(19910315)67:6<1514::aid-cncr2820670609>3.0.co;2-q.Peer-Reviewed Original Research
1990
A Phase 1 Study of Ribavirin in Human Immunodeficiency Virus-Infected Patients
Roberts R, Jurica K, Meyer W, Paxton H, Makuch R. A Phase 1 Study of Ribavirin in Human Immunodeficiency Virus-Infected Patients. The Journal Of Infectious Diseases 1990, 162: 638-642. PMID: 2117625, DOI: 10.1093/infdis/162.3.638.Peer-Reviewed Original ResearchConceptsPeripheral blood mononuclear cellsPhase 1 studyDaily dosesAdverse reactionsTreatment groupsHuman immunodeficiency virus-infected patientsPatients' peripheral blood mononuclear cellsHIV surrogate markersT lymphocyte subsetsVirus-infected patientsClinical adverse reactionsAnti-HIV effectDemonstrable beneficial effectsHuman immunodeficiency virusBlood mononuclear cellsOral ribavirinP24 antigenemiaLymphocyte subsetsTotal lymphocytesSerum betaImmunodeficiency virusLymphocyte markersMononuclear cellsLymphocyte populationsSurrogate marker